- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06746389
Effects of Vitamin D Supplementation on Muscle Protein Synthesis (VIPER)
Effects of Vitamin D Supplementation on Myofibrillar Protein Synthesis Rates in Rested and Exercised Muscle in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial
Background: Healthy adults maintain muscle tissue by continuously building up and breaking down muscle proteins throughout the day. Studies have shown that vitamin D (VitD) is essential for maintaining muscle mass by activating cellular pathways involved in building muscle via muscle protein synthesis (MPS). Although, various candidate molecules have been identified in animal models, it is not known whether these pathways are activated in humans. Interestingly, animal studies indicate that 20% of VitD is stored in human muscle cells, which may help maintain VitD sufficiency during winter in Northern latitudes when there is not much sunlight Objectives: We will investigate whether VitD supplementation increases the MPS response to feeding and exercise, VitD storage in muscle cells, and cellular pathways that are involved in healthy sedentary or moderately active adults.
Methods: Participants will consume either a placebo (sucrose) or the intervention (vitamin D3, 3000IU/day) for 12 weeks in a double-blinded randomised study. Before and after the intervention participants will have body composition measured. Blood and muscle samples will be taken before and after a bout of exercise and ingestion of 20 g protein in order to measure MPS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent in vitro studies have demonstrated an anabolic role of vitamin D directly targeting skeletal muscle via vitamin D receptors (VDR) present in myotubes [1,2,3]. However, this has yet to be translated to in vivo human models.
25-hydroxyvitamin-D (25OHD) is the primary circulating metabolite and reference measurement for vitamin D status. This may then either be converted to 24,25-dihydroxyvitamin D3 (24,25OHD) to prevent intoxication [4] or be activated in the kidneys to 1,25-dihydroxyvitamin D (1,25OHD)[5].
Evidence support a biological role for 1,25OHD in skeletal muscle[1-4,7]. With focus on muscle hypertrophy, a study demonstrated that 25OHD can also be activated to 1,25OHD in myotubes[8] and promote cell proliferation, growth and differentiation of myocytes in in vitro skeletal muscle cells[7,9-13]. The mechanisms proposed include (i) gene expression of endocytic receptors for vitamin D binding protein (VDP) (megalin/cubulin) on the muscle cell surface membrane and (ii) high affinity for VDP to bind to actin inside the muscle cell. Furthermore, epidemiological studies support a positive role for vitamin D in human muscle function[14-21] and mechanistic studies implicate intracellular 25OHD in the regulation of protein metabolism. Cell culture and in vivo animal models demonstrate that 25OHD activates anabolic cell signalling proteins of the mTORC1 pathway in response to anabolic stimuli[21,22], which translates into an increased stimulation of muscle protein synthesis[17]. Despite these exciting results from cell culture and in vivo animal studies, no study has replicated these findings in in vivo human models.
The length of the intervention in studies investigating the effects of vitamin D supplementation on muscle health outcomes and MPS varies between studies; however, evidence supports improvements in fast-twitch muscle fibres in elderly women[18], muscle strength in humans and animals and an increased in MPS in rats and mice following a minimum of 12 weeks intervention [22]. Thus, this study plans to have 12 weeks of intervention to ensure there is sufficient time for a physiologically effect to take place. Seasonal variations in blood 25OHD concentrations have been evaluated in Caucasians residing in Northern Ireland[4]. Thirty-four percent were deficient (<25nmol/L) in winter months[4]; however, despite insufficient sunlight in winter to synthesise vitamin D in skin, a significant proportion of a population resident in the same latitude, in Scotland, maintained blood 25OHD concentrations >50nmol/L[6]. These data and a recent review[8] suggest that humans have evolved a storage mechanism, which allows 25OHD, produced in the summer, to be conserved and used more efficiently in winter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Devon
-
Exeter, Devon, United Kingdom, EX1 2LU
- University of Exeter
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adults aged 18 - 45
- Sedentary and moderately active (NDNS)
Exclusion Criteria:
- Any diagnosed acute or chronic condition
- Very active (NDNS)
- On medication apart from contraceptive pill
- Not taking vitamin supplementation for 30 days before enrolling
- Not having been exposed to the sun (synthesising months - any country) in the previous 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Vitamin D
3000 IU/Day 12 weeks
|
Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
|
|
Placebo Comparator: Placebo
Placebo one/day 12 weeks
|
Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fractional synthetic rate of amino acid incorporation into myofibrillar protein
Time Frame: 12 weeks x 4 time points
|
Fractional synthetic rate of amino acid incorporation into myofibrillar protein
|
12 weeks x 4 time points
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phosphorylated mTOR
Time Frame: 12 weeks x 4 time points
|
Phosphorylated mTOR response following 12 weeks intervention vs placebo
|
12 weeks x 4 time points
|
|
Total mTOR
Time Frame: 12 weeks x 2 time points
|
Total mTOR following 12 weeks intervention
|
12 weeks x 2 time points
|
|
Plasma amino acid kinetics
Time Frame: 12 weeks x 16 time points
|
Plasma amino acid kinetics in response to intervention vs. placebo
|
12 weeks x 16 time points
|
|
Glucose
Time Frame: 12 weeks x 16 time points
|
Glucose response to intervention vs. placebo
|
12 weeks x 16 time points
|
|
Insulin
Time Frame: 12 weeks x 14 time points
|
Insulin response to intervention vs. placebo
|
12 weeks x 14 time points
|
|
Leg press
Time Frame: 12 weeks x 1 x1
|
Leg press - strength
|
12 weeks x 1 x1
|
|
Leg extension
Time Frame: 12 weeks 1 x 1
|
Leg extension - Strength
|
12 weeks 1 x 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Raquel Revuelta Iniesta, PhD, University of Exeter
Publications and helpful links
General Publications
- Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006 Mar;81(3):353-73. doi: 10.4065/81.3.353.
- Tieland M, Brouwer-Brolsma EM, Nienaber-Rousseau C, van Loon LJ, De Groot LC. Low vitamin D status is associated with reduced muscle mass and impaired physical performance in frail elderly people. Eur J Clin Nutr. 2013 Oct;67(10):1050-5. doi: 10.1038/ejcn.2013.144. Epub 2013 Aug 14.
- Vignale K, Greene ES, Caldas JV, England JA, Boonsinchai N, Sodsee P, Pollock ED, Dridi S, Coon CN. 25-Hydroxycholecalciferol Enhances Male Broiler Breast Meat Yield through the mTOR Pathway. J Nutr. 2015 May;145(5):855-63. doi: 10.3945/jn.114.207936. Epub 2015 Mar 18.
- Salles J, Chanet A, Giraudet C, Patrac V, Pierre P, Jourdan M, Luiking YC, Verlaan S, Migne C, Boirie Y, Walrand S. 1,25(OH)2-vitamin D3 enhances the stimulating effect of leucine and insulin on protein synthesis rate through Akt/PKB and mTOR mediated pathways in murine C2C12 skeletal myotubes. Mol Nutr Food Res. 2013 Dec;57(12):2137-46. doi: 10.1002/mnfr.201300074. Epub 2013 Aug 9.
- Chiang CM, Ismaeel A, Griffis RB, Weems S. Effects of Vitamin D Supplementation on Muscle Strength in Athletes: A Systematic Review. J Strength Cond Res. 2017 Feb;31(2):566-574. doi: 10.1519/JSC.0000000000001518.
- Beals JW, Sukiennik RA, Nallabelli J, Emmons RS, van Vliet S, Young JR, Ulanov AV, Li Z, Paluska SA, De Lisio M, Burd NA. Anabolic sensitivity of postprandial muscle protein synthesis to the ingestion of a protein-dense food is reduced in overweight and obese young adults. Am J Clin Nutr. 2016 Oct;104(4):1014-1022. doi: 10.3945/ajcn.116.130385. Epub 2016 Sep 7.
- Montenegro KR, Cruzat V, Carlessi R, Newsholme P. Mechanisms of vitamin D action in skeletal muscle. Nutr Res Rev. 2019 Dec;32(2):192-204. doi: 10.1017/S0954422419000064. Epub 2019 Jun 17.
- van Vliet S, Fappi A, Reeds DN, Mittendorfer B. No independent or combined effects of vitamin D and conjugated linoleic acids on muscle protein synthesis in older adults: a randomized, double-blind, placebo-controlled clinical trial. Am J Clin Nutr. 2020 Nov 11;112(5):1382-1389. doi: 10.1093/ajcn/nqaa240.
- SANC. (2007) Update on Vitamin D: Position Statement by the Scientific Advisory Committee on Nutrition. London: TSO
- Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Munoz-Canoves P. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle. 2011 May 4;1(1):21. doi: 10.1186/2044-5040-1-21.
- Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development. 2012 Aug;139(16):2845-56. doi: 10.1242/dev.069088.
- Owens DJ, Sharples AP, Polydorou I, Alwan N, Donovan T, Tang J, Fraser WD, Cooper RG, Morton JP, Stewart C, Close GL. A systems-based investigation into vitamin D and skeletal muscle repair, regeneration, and hypertrophy. Am J Physiol Endocrinol Metab. 2015 Dec 15;309(12):E1019-31. doi: 10.1152/ajpendo.00375.2015. Epub 2015 Oct 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 201021/B/03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Protocol and ethics can be shared on request
Information identifier: 201021/B/03Information comments: Ethics documents and study protocol can be shared on request. Please contact PI Dr Raquel Revuelta Iniesta at r.revuelta-iniesta@exeter.ac.uk or the PHSS Ethics Committee at a.guy@exeter.ac.uk
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Effects on MPS
-
University of ZurichCompletedPhysiological Effects of Vitamin DSwitzerland
-
University of UlsterAgri-Food and Biosciences Institute; Foodovation North West Regional College; Kenedy Bacon and other collaboratorsEnrolling by invitationVitamin D Status | Vitamin D Biofortification | Vitamin D FortificationUnited Kingdom
-
Indiana UniversityPurdue University; Indiana University School of MedicineRecruitingT Cell Response to Dried Plum | Vitamin D Influence on Immune Response | Dried Plum and Immune FunctionUnited States
-
University of UlsterNorthern Ireland Executive; HSC Public Health AgencyCompletedVitamin D Status | Vitamin D ConcentrationUnited Kingdom
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenRecruitingVitamin D | Vitamin D and Calcium HomeostasisBelgium
-
Horopito LimitedAtlantia Food Clinical TrialsCompleted
-
University Hospital, Clermont-FerrandTerminated
-
Hospices Civils de LyonCompleted
-
University of UlsterDairy Council for Northern Ireland; Agri-food & Biosciences Institute; Center...Completed
-
Factors Group of Nutritional Companies Inc.Completed
Clinical Trials on 3000 IU per Day Spray
-
Joben Bio-Medical Co., Ltd.Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaboratorsUnknownRadiodermatitisTaiwan
-
TCM Biotech International Corp.Recruiting
-
ValbiotisBiofortis Mérieux NutriSciencesCompletedDiabetes type2 | Prediabetic State | DysglycemiaItaly, France, Germany, Poland, Romania, Bulgaria, Hungary
-
Spectrum Pharmaceuticals, IncCompletedSafety | Phosphate Binding CapacityUnited States
-
University of California, DavisCompletedHealthy, Postmenopausal Women
-
Daping Hospital and the Research Institute of Surgery...Fujian Cancer Hospital; Affiliated Hospital of Jiangnan University; Zhongnan... and other collaboratorsNot yet recruiting
-
Serenity Pharmaceuticals, Inc.Completed
-
University of Colorado, DenverTemple UniversityCompleted
-
University of ConnecticutCompleted